AlphanoxLtd Balance Sheet Health

Financial Health criteria checks 4/6

AlphanoxLtd has a total shareholder equity of ₩23.6B and total debt of ₩25.8B, which brings its debt-to-equity ratio to 109.3%. Its total assets and total liabilities are ₩58.6B and ₩35.0B respectively.

Key information

109.3%

Debt to equity ratio

₩25.78b

Debt

Interest coverage ration/a
Cash₩11.68b
Equity₩23.60b
Total liabilities₩35.04b
Total assets₩58.63b

Recent financial health updates

Recent updates

Is Solco Biomedical (KOSDAQ:043100) Using Debt In A Risky Way?

Jun 27
Is Solco Biomedical (KOSDAQ:043100) Using Debt In A Risky Way?

Solco Biomedical Co., Ltd.'s (KOSDAQ:043100) 27% Dip In Price Shows Sentiment Is Matching Revenues

Jun 27
Solco Biomedical Co., Ltd.'s (KOSDAQ:043100) 27% Dip In Price Shows Sentiment Is Matching Revenues

Solco Biomedical Co., Ltd.'s (KOSDAQ:043100) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Feb 27
Solco Biomedical Co., Ltd.'s (KOSDAQ:043100) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Financial Position Analysis

Short Term Liabilities: A043100's short term assets (₩33.5B) exceed its short term liabilities (₩33.0B).

Long Term Liabilities: A043100's short term assets (₩33.5B) exceed its long term liabilities (₩2.1B).


Debt to Equity History and Analysis

Debt Level: A043100's net debt to equity ratio (59.8%) is considered high.

Reducing Debt: A043100's debt to equity ratio has increased from 35.2% to 109.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A043100 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: A043100 has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 7.4% each year.


Discover healthy companies